Striving to make advances in lung cancer research

For over 30 years, Gilead has studied medicines for life-threatening diseases like lung cancer. With multiple clinical trials in non-small cell lung cancer (NSCLC), we are striving to innovate with next-generation therapies, combinations, and technologies as we seek to deliver improved outcomes and provide hope for people living with lung cancer.

Featured trials

STATUSRecruiting

Extensive stage small cell lung cancer: GS-US-600-6165

EVOKE-SCLC-04: A Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer.

STATUSRecruitment Complete

Lung cancer: GS-US-624-6376

VELOCITY-Lung: A phase 2 platform study evaluating the safety and effectiveness of novel treatment combinations in people living with lung cancer.

 
View more trials

Our mission is to support your journey

229,410

In 2026, it’s estimated that there will be nearly 229,410 new cases of lung cancer in the United States.

Source: Cancer.org

A lung cancer diagnosis can feel isolating, but remember, you are not alone. There are clinical trial options available that may play a role in your lung cancer journey.

What we are studying?

Non-small cell lung cancer

  • Non-small cell lung cancer (NSCLC) is cancer of the cells that line the surface of the lung airways
  • NSCLC includes squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, among others
  • About 80% to 85% of lung cancer cases are NSCLC
  • NSCLC is often diagnosed in individuals around the age of 70

Small cell lung cancer

  • Small cell lung cancer (SCLC) includes small cell carcinoma (oat cell cancer) and combined small cell carcinoma
  • SCLC is the most aggressive form of lung cancer. Approximately 15% of lung cancer diagnoses are SCLC
  • In 60% of SCLC cases, the cancer has spread before it is diagnosed
  • SCLC is slightly more common in men than women, and most diagnoses occur around 69 years of age

Sources: Cancer.org, NIH National Library of Medicine, YaleMedicine.org, Voelker R, 2025, Dee EC et al, 2025

Active trials, not recruiting

View more trials

The lung cancer community

Our partnerships with lung cancer advocacy organizations committed to change

Lung Cancer Action Network logo.

Partnership with LungCAN

Lung Cancer Action Network members collaborate on strategic projects to increase their collective impact and serve those at risk for or living with lung cancer more efficiently and effectively. Lung Cancer Action Network cultivates a cooperative environment, encourages the exchange of ideas, fosters effectiveness and efficiency, and gives member organizations a united voice behind a shared cause. Lung Cancer Action Network honors and respects each member organization's brand, personality, and unique mission.

Learn more

Advocacy groups

Organizations committed to research, education, awareness, and support for the lung cancer community

American Cancer Society
GO2 for Lung Cancer
International Association for the
Study of Lung Cancer (IASLC)
LIVELUNG
Lung Cancer Foundation of America
Lung Cancer Research Foundation
LUNGEVITY Foundation

Gilead is not responsible for the security, privacy, or other policies or practices on any of the third-party websites. These links are to external third-party sites not affiliated with or controlled by Gilead.

Join Gilead Trial Connect and help advance clinical research. Your participation is key to developing future treatments.

Sign up now